Dr. Dan Feig is a professor of pediatrics and division director of Pediatric Nephrology at University of Alabama, Birmingham (UAB). He received his undergraduate degree in Molecular Biology at Princeton University and his medical degree and PhD in biochemistry at University of Washington. He also received an M.S. in Clinical Investigation at Baylor College of Medicine. He did his residency in Pediatrics at Children’s Hospital and Regional Medical Center in Seattle and his Pediatric Nephrology fellowship at Boston Children’s Hospital. He was on the pediatric renal faculty at Texas Children’s Hospital and Baylor College of Medicine from 2001until 2011 when he moved to Birmingham to join the faculty at UAB.

In 2011 Dr. Feig joined the faculty of the Department of Pediatrics as a full professor and as Division director of Pediatric Nephrology. In addition to his administrative role as division director, he is medical director of the Pediatric Renal Transplant Program and Co-Director of the Renal Fellowship Program. In terms of hospital/departmental service he is a member of the Serious Safety Events (SSE) team, part of the Solutions for Patient Safety (SPS) program, which is developing bundled programs to reduce patient risk, and the Physician Information Technology Advisory Committee.

Dr. Feig’s current clinical service commitment accounts for a little more than 50% of his time. He has 12 weeks of inpatient service per year, in part to protect the research efforts of his junior faculty. He has outpatient general renal, pediatric hypertension and renal transplant clinics each week and a monthly outreach clinic in Montgomery.

Dr. Feig’s research interest focuses on the physiology of early onset essential hypertension as well as the prevention of hypertensive target organ damage. His studies have shown that uric acid is a mediator of early essential hypertension and uric acid reduction can both treat high blood pressure and prevent its development in certain adolescent populations. He also studies obesity related hypertension in adolescents and is evaluating novel screening and management strategies to mitigate risk of organ damage before weight loss can be successfully achieved. His other recent studies have evaluation the cost effectiveness of hypertension evaluation strategies, management of hypertensive emergencies in infants and the effect of cardiovascular fitness on change in blood pressure. His research has been funded by grants from the NIDDK, NHLBI and NICHD as well as several industry sources.

Dr. Feig has been married for 22 years and has 3 sons ages 18, 14 and 11. His eldest son will be attending Princeton University in Fall 2014 and is currently doing a university sponsored bridge-service year in northern India.

Click here for full CV.

Selected Publications –
  • Silverstein DM, Srivaths PR, Mattison P, Upadhyay K, Midgley L, Moudgil A, Goldstein SL, Feig DI. Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol. 2011 Jul;26(7):1123-8.
  • Shamszad P, Slesnick TC, Smith EO, Taylor MD and Feig DI. Association between left ventricular mass index and cardiac function in pediatric dialysis patients. Pediatr Nephrol. 2012, 27 (5): 835-841.
  • Nagamani SCS, Campeau PM, Shchelochkov O, Guse K, Premkumar MH, Brunetti-Pierri N, Chen YQ, Sun C, Tan Y, Palmer D, Reddy AK, Li L, Slesnick TC, Feig DI, Harrison D, Salviati L, Marini J, Bryan NS, Erez A and Lee B. Long-term correction of Nitric Oxide Deficiency in Argininosuccinic aciduria. Am J Hum Genet. 2012; 90(5):836-46.
  • Soletsky B and Feig DI. Uric acid reduction rectifies pre-hypertension in obese adolescents. Hypertension, 2012; 60(5):1148-56
Current Research Support
1. Pediatric Trials Network (0.6 months effort)
  • Steering committee
  • Amlodipine Pharmacokinetics and in pediatric renal transplant patients
  • Lisinopril Pharmacokinetics and in pediatric renal transplant patients
  • Lisinopril long term safety and efficacy in pediatric renal transplant patients
  1. Funding Source: NIH-NICHD
  2. Investigator Relationship: Steering committee, Site PI
  3. Dates of Funding: Nov 2010-Dec 2013
The goal of this project is to develop a pediatric clinical trials network capable of rapid initiation of studies and efficient enrollment in a wide variety of investigator initiated and pharmaceutical industry clinical trials. Current efforts are in the fields of pediatric hypertension and pediatric infectious disease.

2.    NAPRTCS/CTOT-C (0.3 months effort)
  1. Funding Source: NIH/NIDDK
  2. Investigator Relationship: Site Principal Investigator
  3. Dates of Funding: ongoing
  4. Total Budget: $35,000
3.    The Effects of Urate Lowering Therapy on Inflammation, endothelial function and blood pressure (0.3 months effort)
  2. Investigator Relationship: Investigator (0.6 months effort)
  3. Dates of Funding: October 2012-September 2017
  4. Total Budget: 7,300,813
4.    Pediatric Belatacept Trial
  1. Bristol Myers Squib
  2. Investigator Relationship: Site PI
  3. Dates of Funding: February 2013- January 2014
  4. Total Budget: $257,000